EUCTR2008-000973-40-AT进行中（未招募）1 期
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment
AB SCIENCE0 个研究点目标入组 450 人开始时间: 2010年6月30日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Histologically proven, metastatic or locally advanced non resectable, or recurrent post surgery GIST
- •2.Naïve patient or patient previously treated with imatinib as neoadjuvant/adjuvant who relapsed after imatinib discontinuation
- •3.Measurable tumour lesions with longest diameter = 20 mm using conventional techniques or = 10 mm with spiral CT scan according RECIST criteria
- •4.C-Kit (CD117) positive tumours detected by immuno-histochemically
- •5.ECOG < 1
- •6.Patient with adequate organ function:
- •Absolute neutrophil count (ANC) = 1.5 x 109/L
- •Haemoglobin = 10 g/dL
- •Platelets (PTL) = 75 x 109/L
- •AST/ALT = 3x ULN (= 5 x ULN in case of liver metastases)
- •Gamma GT = 2.5 x ULN (= 5 x ULN in case of liver metastases)
- •Bilirubin = 1.5x ULN (= 3 x ULN in case of liver metastases)
- •Normal Creatinine or if abnormal creatinine, Creatinine clearance = 50 mL/min (Cockcroft and Gault formula)
- •Albumin > 1 x LLN
- •Proteinuria < 30 mg/dL (1+) on the dipstick; in case of proteinuria = 30 mg/dL, 24 hours proteinuria must be = 1.5g
- •7.Patient with life expectancy > 3 months
- •8.Men or women, age =18 years
- •9.Female patient of childbearing potential (entering the study after a menstrual period and who have a negative pregnancy test), who agrees to use two highly effective methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake. Acceptable forms of contraception include:
- •A documented placement of an intrauterine device (IUD) or intrauterine system (IUS) and the use of a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps] used with spermicidal foam/gel/film/cream/suppository)
- •Documented tubal ligation (female sterilization). In addition, a barrier method (condom or occlusive cap [diaphragm or cervical/vault caps] used with spermicidal foam/gel/film/cream/suppository) should also be used
- •Double barrier method: Condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository
- •Any other contraceptive method with a documented failure rate of <1% per year
- •Abstinence
- •Male patients must use medically acceptable methods of contraception if his female partner is pregnant, from the time of the first administration of the study drug until three months following administration of the last dose of study drug. Acceptable methods include:
- •If you have undergone surgical sterilization (vasectomy with documentation of azoospermia) a condom should also be used.
- •Male patients must use two highly effective methods (one for the patient and one for the partner) of medically acceptable forms of contraception during the study and for 3 months after the last treatment intake. The acceptable methods of contraception are as follows:
- •Condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository;
- •Surgical sterilization (vasectomy with documentation of azoospermia) and a barrie
排除标准
- •1.Patient previously treated by tyrosine kinase inhibitors except imatinib in case of inclusion criteria 2
- •2.Patient treated for a cancer other than GIST within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ
- •3.Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
- •4.Patient presenting with cardiac disorders defined by at least one of the following conditions:
- •Patient with recent cardiac history (within 6 months) of:
- •-Acute coronary syndrome
- •-Acute heart failure (class III or IV of the NYHA classification)
- •-Significant ventricular arrhythmia (persistent ventricular tachycardia, ventricular fibrillation, resuscitated sudden death)
- •Patient with cardiac failure class III or IV of the NYHA classification
- •Patient with severe conduction disorders which are not prevented by permanent pacing (atrio-ventricular block 2 and 3, sino-atrial block)
- •Syncope without known aetiology within 3 months
- •Uncontrolled severe hypertension, according to the judgment of the investigator, or symptomatic hypertension
- •5.Patient with history of poor compliance or history of drug/alcohol abuse, or excessive alcohol beverage consumption that would interfere with the ability to comply with the study protocol, or current or past psychiatric disease that might interfere with the ability to comply with the study protocol or give informed consent
- •6.Patient with any condition that the physician judges as detrimental to subjects participating in this study, including any clinically important deviations from normal clinical laboratory values or concurrent medical events
- •Previous treatment
- •7.Treatment with any investigational agent within 4 weeks prior baseline
- •8.Treatment by imatinib as neoadjuvant/adjuvant therapy within 4 weeks prior baseline
研究者
相似试验
进行中（未招募）
不适用
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentEUCTR2008-000973-40-HUAB SCIENCE222
招募中
3 期
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentGISTNL-OMON44826AB Science20
暂停
不适用
A study to evaluate the efficacy and safety of Aceinavir combined with supportive Standard of Care (SoC) in hospitalized patients with moderate coronavirus disease (COVID-19)CTRI/2020/08/027284Dyuthi Biosciences Private Limited
进行中（未招募）
1 期
A prospective, multicenter, randomized, open-label, active-controlled, phase III study to compare efficacy and safety of masitinib to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentGastro-intestinal stromal tumour (GIST)MedDRA version: 17.0Level: PTClassification code 10051066Term: Gastrointestinal stromal tumourSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000973-40-GRAB SCIENCE450
进行中（未招募）
1 期
A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatmentgastro-intestinal stromal tumourMedDRA version: 9.1 Level: LLT Classification code 10051066 Term: Gastrointestinal stromal tumourEUCTR2008-000973-40-FRAB SCIENCE222